RxDoctor Payments Data

Celso Lobao, MD

Psychiatry · Raleigh, NCNPI 1447259676

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,960 of the $27,836 with a category attached, or 93.3%. AbbVie accounts for 98.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $17,311 and has fallen 99.9% since, to $15 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,836in general payments, 2019–2025

Across 158 payments — averaging $176.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Sunovion Pharmaceuticals Inc.$147
  • Neurocrine Biosciences, Inc.$122
  • Johnson & Johnson$69
  • Teva Pharmaceuticals USA, Inc.$24

What the payments were for

  • Speaking & faculty fees$25,96093%
  • Food & beverage$1,8767%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,836 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$24,443
Medicare patients
25
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$15,654
Clomipramine Hcl12$4,476
Mirtazapine98$1,416
Olanzapine18$1,155
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$860
Lorazepam84$805
Methylphenidate Hcl23$769
Zaleplon11$597
Venlafaxine Hcl ErVenlafaxine Hcl28$589
Clonazepam83$578
Bupropion XlBupropion Hcl44$565
Imipramine Hcl12$555
Doxepin Hcl15$444
Trazodone Hcl37$424
Lamotrigine40$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$27,474$15,65411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →